Inventor · disambiguated record
Thomas Chittenden
Also filed as: CHITTENDEN THOMAS · CHITTENDEN THOMAS D
20 granted patents·6 pending applications·228 citations·filing 1994–2023
95Inventor score
Files withIMMUNOGEN INC18APOPTOSIS TECHNOLOGY INC3SETIADY JULIANTO3CHITTENDEN THOMAS D1IMMNOGEN INC1
Top patents by PatentIndex Score
26 records- 0195US11834498B2Biparatopic FR-alpha antibodies and immunoconjugatesIMMUNOGEN INC·Filed 2022·Granted Dec 5, 2023·2 cites·30 claims
- 0294US10875925B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2020·Granted Dec 29, 2020·3 cites·12 claims
- 0394US10077313B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2016·Granted Sep 18, 2018·12 cites·28 claims
- 0493US11332535B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2020·Granted May 17, 2022·2 cites·14 claims
- 0593US10919969B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2017·Granted Feb 16, 2021·4 cites·4 claims
- 0693US8790649B2EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jul 29, 2014·26 cites·37 claims
- 0792US11396543B2Biparatopic FR-α antibodies and immunoconjugatesIMMNOGEN INC·Filed 2020·Granted Jul 26, 2022·4 cites·47 claims
- 0891US7202346B2Antibodies to non-shed Muc1 and Muc16, and uses thereofIMMUNOGEN INC·Filed 2003·Granted Apr 10, 2007·62 cites·37 claims
- 0988US10442865B2Methods of use of anti-CD123 antibodies and antigen-binding fragments thereofIMMUNOGEN INC·Filed 2018·Granted Oct 15, 2019·4 cites·16 claims
- 1085US9233171B2Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugateSETIADY JULIANTO·Filed 2012·Granted Jan 12, 2016·4 cites·51 claims
- 1182US2024182560A1Biparatopic fr-alpha antibodies and immunoconjugatesIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 1281US11897961B2Anti-CD123 antibodies and conjugates and derivatives thereofIMMUNOGEN INC·Filed 2022·Granted Feb 13, 2024·0 cites·11 claims
- 1381US5672686ABcl-Y - specific antibodiesIMMUNOGEN INC·Filed 1994·Granted Sep 30, 1997·45 cites·6 claims
- 1480US9125896B2EGFR-binding molecules and immunoconjugates thereofIMMUNOGEN INC·Filed 2013·Granted Sep 8, 2015·3 cites·39 claims
- 1578US5656725APeptides and compositions which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1995·Granted Aug 12, 1997·39 cites·2 claims
- 1672US9238690B2Non-antagonistic EGFR-binding molecules and immunoconjugates thereofSETIADY JULIANTO·Filed 2011·Granted Jan 19, 2016·1 cites·38 claims
- 1771US2009081705A1Novel peptides and compositions which modulate apoptosisCHITTENDEN THOMAS D·Filed 2008·Application pending·0 cites
- 1870US6221615B1Peptides and compositions which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1999·Granted Apr 24, 2001·15 cites·2 claims
- 1967US7358088B2Peptides and compositions which modulate apoptosisIMMUNOGEN INC·Filed 2006·Granted Apr 15, 2008·1 cites·6 claims
- 2050US7202024B2bbc3 Gene promoter and methods for identifying modulators of apoptosis and bbc3 gene expression using a bbc3 gene promoterIMMUNOGEN INC·Filed 2001·Granted Apr 10, 2007·1 cites·83 claims
- 2150US2021403594A1Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereofIMMUNOGEN INC·Filed 2019·Application pending·0 cites
- 2248US7097982B2Peptides and compositions which modulate apoptosisIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·0 cites·15 claims
- 2348US2016060345A1Novel EGFR-Binding Molecules and Immunoconjugates ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 2447US2016017053A1Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates ThereofIMMUNOGEN INC·Filed 2015·Application pending·0 cites
- 2541US2018230218A1Met antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2018·Application pending·0 cites
- 2630US5863795ANucleic acids that encode peptides which modulate apoptosisAPOPTOSIS TECHNOLOGY INC·Filed 1997·Granted Jan 26, 1999·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Thomas Chittenden files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →